James J. Dignam to Carcinoma, Intraductal, Noninfiltrating
This is a "connection" page, showing publications James J. Dignam has written about Carcinoma, Intraductal, Noninfiltrating.
Connection Strength
0.292
-
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011 Mar 16; 103(6):478-88.
Score: 0.092
-
Mammographic density and breast cancer after ductal carcinoma in situ. J Natl Cancer Inst. 2004 Oct 06; 96(19):1467-72.
Score: 0.059
-
Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001 Aug; 28(4):400-18.
Score: 0.047
-
Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer. 1999 Aug 01; 86(3):429-38.
Score: 0.041
-
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12; 353(9169):1993-2000.
Score: 0.041
-
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15; 20(20):4141-9.
Score: 0.013